Clime Capital Limited Convertible Notes (CAM Notes) Offer - CAM Notes (ASX code: CAMG) offer a fixed interest return of 6.5% per annum, payable monthly, with a maturity date of 30 November 2028 [11] - The minimum investment is $2,000 (2,000 Notes @ $1.00 each) [11] - CAM Notes are convertible to ordinary CAM shares at $1.00 on a 1:1 basis anytime before maturity [11] - The notes are unsecured and unsubordinated, ranking behind secured creditors and equal with other unsubordinated debt [11] CAM.ASX Strategy - CAM.ASX is a Listed Investment Company equities portfolio focused on generating income above ASX 200 Dividend yield [18] - CAM.ASX leverages up to 40% of portfolio value to generate an interest margin and improve yield [18] - Clime Capital's Gross Asset Value (GAV) is $155 million as of 18 August 2025 [30] - Clime Capital (CAM.ASX) has 149 million shares on issue, with a market capitalization of $105 million and NTA (Net Tangible Assets) per share of $0.82 [30] Private Credit Market - Australia's non-bank lending sector has grown to $310 billion as of April 2025, representing approximately 8% of the total credit market of $3.93 trillion [46] - In January 2017, non-bank lending was $133 billion compared to a total credit market of $2.6 trillion [46] - The portfolio mix for credit investments is approximately 60-90% in private loans and 10-40% in liquid credit/cash [55]

Financial Performance - Revenue decreased by 1% to $59.5 million in FY25 compared to FY24[24] - Net Profit After Tax (NPAT) increased by 17% to $10.4 million in FY25 compared to FY24[24] - The company achieved a record quarterly profit before tax of $4.3 million from revenue of $16.8 million during June Q4[24] - Earnings Per Share (EPS) reached 7.4 cents, and a fully franked dividend of 4.5 cents per share was declared[24] Balance Sheet - Cash and cash equivalents increased by 2% to $12.2 million in 2025[25] - Total assets increased by 7% reaching $72.8 million in 2025[25] - Total equity increased by 8% reaching $60.2 million in 2025[25] Acquisitions - The company acquired the remaining 50% of Orbis Mining on 26 July 2024 for $3.91 million upfront consideration[20] - The company acquired 100% of Labfit on 13 December 2024 for $1.16 million upfront consideration[20] Segment Performance - Consumables sales revenue increased by 2% to $19.3 million in FY25[28] - Precious Metals sales revenue remained flat at $21.5 million in FY25[31] - Capital Equipment sales revenue increased by 4% to $22.6 million in FY25[35]

Financial Performance - XP Inc's client assets, AUM, and AUA reached R$1.9 trillion, a 17% increase year-over-year[10] - Gross Revenue increased by 4% year-over-year to R$4.7 billion[12] - The company's EBT was R$1.3 billion, a 5% decrease year-over-year[12] - Net Income grew by 18% year-over-year, with a diluted EPS growth of 30% CAGR[15] - The company's ROE was 24.4%, a 223 bps increase year-over-year[14] Retail Investments - Retail Net New Money amounted to R$16 billion[26] - Retail revenue increased by 9% year-over-year to R$3.577 billion[66] - Equities and Fixed Income are the main contributors in Retail revenue[69] Wholesale - Institutional, Corporate, and Issuer Services Gross Revenue reached R$3.619 billion LTM[54] - Investment Banking DCM Volume was R$34 billion[54] Capital Management - The company's BIS Ratio is 20.1%[14, 105] - The company's VaR is R$28 million, or 13 bps of Equity[107]

COMPANY OVERVIEW August 18, 2025 1 Disclaimer This presentation and the accompanying oral presentation contain "forward-looking" statements that are based on management's beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our business plans and objectives, potential growth opportunities, competitive position, industry environme ...

Financial Performance - Q4 2025 Remaining Performance Obligation (RPO) reached $158 billion, a 24% year-over-year increase[11] - Next-Generation Security Annual Recurring Revenue (NGS ARR) for Q4 2025 was $558 billion, up 32% year-over-year[11] - Q4 2025 revenue totaled $254 billion, representing a 16% year-over-year growth[11] - The company's FY 2025 adjusted free cash flow was $351 billion, a 12% increase year-over-year, with an adjusted free cash flow margin of 380%[11] - FY 2025 non-GAAP operating margin was 288%, a 150 basis point increase year-over-year, and non-GAAP EPS was $334, up 18% year-over-year[11] Platformization and Customer Growth - The company has approximately 1,400 total platformizations[14] - Platformized customers exhibit a net retention rate (NRR) of 120%[14] - The number of customers with over $5 million in NGS ARR increased by 51% year-over-year, reaching 156, while those with over $10 million in NGS ARR increased by 50% year-over-year, totaling 51[18] Network Security and SASE - Network Security NGS ARR reached $39 billion, growing approximately 35% year-over-year[21] - SASE ARR grew by 35% year-over-year[23] - The company has approximately 6,350 SASE customers, an 18% increase year-over-year[23] Cortex and Security Operations - Total Cortex & Prisma Cloud ARR is approximately $17 billion, up approximately 25% year-over-year[24] - The company has approximately 400 XSIAM customers, more than double year-over-year[25]

2 3 3 2Q25 Gross Profit and Gross Margin were impacted by $6.4 million in non-cash charges related to obsolete inventory adjustments and write-down of capitalized costs related to incomplete projects $8.0 $8.8 $9.8 $10.6 $11.8 $- $2.0 $4.0 $6.0 $8.0 $10.0 $12.0 2Q24 3Q24 4Q24 1Q25 2Q25 $ in millions Over Last 5 Quarters 5 Repeat and Recurring Service Revenue All comparisons are Q2 -2025 year-over-year, unless otherwise noted Service Revenues consist of repeat charging service revenues, recurring network fee ...

Roadshow presentation 9M 2024/25 Making life easier Strive25: Sustainable Growth Leadership Fikria , User, Continence Care Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements are based on Coloplast's current expectations, estimates and assumptions and based on the ...

Results 2Q25 Transf rming lives with our energy Disclaimer Certain statements and estimates in this material may represent expectations about future events or results which are subject to risks and uncertainties that may be known or unknown. There is no guarantee that events or results will occur as referred to in these expectations. These expectations are based on the present assumptions and analyses from the point of view of our management, in accordance with their experience and other factors such as the ...

Q2 2025 Highlights - Transactions reached 397,000, a 26% year-over-year growth[26] - The company achieved record revenue of $74 million, a 31% year-over-year increase[26] - The platform has expanded to include 75 carriers[26] Financial Performance - Q2 2025 revenue was $74 million, exceeding the guidance of $70 million - $71 million[55] - Adjusted EBITDA for Q2 2025 was $(29) million, aligning with the guidance of $(29) million - $(28) million[55] - Non-IFRS gross margin reached 735% for Q2 2025, compared to 720% in Q2 2024[75] Guidance - Q3 2025 transaction guidance is 419,000 - 425,000, representing a 24%-25% year-over-year growth[69] - Q3 2025 revenue is projected to be $76 million - $77 million, a 23%-25% year-over-year increase[69] - Full year 2025 revenue guidance is $295 million - $300 million, reflecting a 24%-26% year-over-year growth[69] - Full year 2025 Adjusted EBITDA is expected to be $(109) million - $(105) million[69]

Tonmya Approval and Launch - TonmyaTM is the first FDA-approved medicine for fibromyalgia in over 15 years[1,13] - Tonix is well-positioned to support the commercial launch of TonmyaTM, expected in Q4 2025[13] - Tonix ended Q2 2025 with approximately $125 million in cash and cash equivalents and raised approximately $50 million in Q3 2025 through equity sales[41] - The company anticipates its cash runway will support the launch and other operations into Q3 2026[13,41] Clinical Efficacy and Safety - Clinical trials demonstrated durable reduction in fibromyalgia pain with TonmyaTM[22] - In Trial 1, the TONMYA group showed a change from baseline of -1.9 compared to -1.5 in the placebo group, with a p-value of 0.010[28] - In Trial 3, the TONMYA group showed a change from baseline of -1.8 compared to -1.2 in the placebo group, with a p-value of less than 0.001[29] - A greater percentage of study participants taking Tonmya experienced a clinically meaningful (≥30%) improvement in their pain after three months, compared to placebo[35] - The most common adverse reactions (incidence ≥2% and at a higher incidence in TONMYA-treated patients compared to placebo-treated patients) were oral hypoesthesia, oral discomfort, abnormal product taste, somnolence, oral paresthesia, oral pain, fatigue, dry mouth, and aphthous ulcer[24,40,94] Market Opportunity and Commercial Strategy - Over 10 million people in the US are living with fibromyalgia[13,50] - Approximately 5% of fibromyalgia-diagnosing HCPs write approximately 70% of fibromyalgia prescriptions[62]